ProMIS Neurosciences (PMN) CDO awarded 50,000 stock options

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. reported that Chief Development Officer Johanne Kaplan received a grant of options to acquire 50,000 Common Shares. The options have an exercise price of $10.77 per share and expire on May 20, 2036.

The award was granted at no cost and vests ratably over four years, subject to her continued service with the company. This filing reflects routine equity compensation and does not involve any open-market purchases or sales of the company’s shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kaplan Johanne

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Option (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 50,000 options Exercise price: $10.77 per share Expiration date: May 20, 2036 +1 more

4 metrics

Options granted 50,000 options Grant of options to acquire Common Shares

Exercise price $10.77 per share Stock option exercise price

Expiration date May 20, 2036 Option term end date

Underlying shares 50,000 Common Shares Shares subject to the option grant

Key Terms

Option (right to buy), Grant, award, or other acquisition, Common Shares, vest ratably over four years

4 terms

Option (right to buy) financial

"security_title: "Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

vest ratably over four years financial

"The shares subject to this option shall vest ratably over four years"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaplan Johanne

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO M4S 3E2

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$10.77	05/20/2026		A		50,000		(1)	05/20/2036	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

	/s/ Max A. Milbury, Attorney in Fact for Johanne Kaplan	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ProMIS Neurosciences (PMN) report for Johanne Kaplan?

ProMIS Neurosciences reported a stock option grant to Chief Development Officer Johanne Kaplan for 50,000 Common Shares. The options are a compensation award, not an open-market trade, and give her the right to buy shares at a fixed price in the future.

What are the key terms of Johanne Kaplan’s 50,000 ProMIS Neurosciences options?

Johanne Kaplan received options on 50,000 ProMIS Neurosciences Common Shares with an exercise price of $10.77 per share. The options expire on May 20, 2036, providing a long-dated incentive tied to the company’s share performance over time.

How do Johanne Kaplan’s ProMIS Neurosciences options vest over time?

The 50,000 options awarded to Johanne Kaplan vest ratably over four years. Vesting is conditioned on her continued service to ProMIS Neurosciences through each vesting date, aligning her compensation with ongoing employment and long-term company performance.

Did Johanne Kaplan buy or sell ProMIS Neurosciences shares in this Form 4?

This Form 4 does not show any open-market buying or selling of ProMIS Neurosciences shares by Johanne Kaplan. It reports only a grant of stock options as compensation, which gives a future right to purchase shares at a fixed exercise price.

How many ProMIS Neurosciences derivative securities does Johanne Kaplan hold after this grant?

After this transaction, Johanne Kaplan holds 50,000 derivative securities in the form of stock options. Each option relates to one underlying Common Share, so the award represents potential future ownership of up to 50,000 ProMIS Neurosciences shares if exercised.